Micronized pregnenolone to support cognitive function, mood, stress resilience, and healthy hormone synthesis.*
What It Does
Pregnenolone is a neurosteroid and hormone precursor that plays a vital role in the production of cortisol, progesterone, estrogen, testosterone, and other steroid hormones.* It may support mood, focus, and the body’s adaptive response to stress as levels decline with age.*
How It Works
• Pregnenolone (Micronized): A bioavailable form of the parent steroid hormone that supports adrenal, reproductive, and neurological function.*[1]
• Neurosteroid Activity: Synthesized in the brain and peripheral nervous system, pregnenolone modulates GABA and NMDA receptors and influences neuroplasticity via BDNF.*[2,3,4,5]
• Hormone Precursor: Serves as the first step in the synthesis of key hormones including cortisol and sex hormones, influencing metabolism, immune balance, and reproductive health.*[1,6]
• Cognitive and Mood Support: Clinical trials suggest pregnenolone supplementation supports focus, working memory, and mood, particularly in populations under cognitive or emotional strain.*[7,8,9]
• Age-Related Optimization: Endogenous pregnenolone production decreases with age. Pregnenolone supports mental stamina and resilience.*[6,10]
• Clinical Dosing Evidence: Human studies have used 30–500 mg daily to support quality of life, attention, and cognitive performance in certain populations.*[7,8,9]
Who It’s For
Ideal for adults seeking support for healthy mood, cognitive function, or hormonal balance, especially during periods of stress.*
Special Features
ARG offers Pregnenolone (micronized) for enhanced bioavailability in 50 mg and 100 mg strength options to accommodate individualized, evidence-informed protocols.*
Pregnenolone helps bridge the gap between hormone synthesis and brain health, supporting multiple systems through a foundational neurosteroid pathway.*
References
1. Murugan S, et al. J Biol Chem. 2019;294(12):4596–607.
2. Mathis C, et al. Psychopharmacology (Berl). 1994;116(2):201–6.
3. Mathis C, et al. Neuropharmacology. 1996;35(8):1057–64.
4. Pierce SR, et al. Mol Pharmacol. 2022;101(2):68–77.
5. Charalampopoulos I, et al. Ann N Y Acad Sci. 2006;1088:139–52.
6. Vallee M, et al. Brain Res Brain Res Rev. 2001;37(1–3):301–12.
7. Naylor JC, et al. JAMA Netw Open. 2020;3(3):e200287. doi:10.1001/jamanetworkopen.2020.0287
8. Kreinin A, et al. Clin Schizophr Relat Psychoses. 2017;10(4):201–10.
9. Ritsner MS, et al. J Clin Psychiatry. 2010;71(10):1351–62.
10. Naert G, et al. Psychoneuroendocrinology. 2007;32(8–10):1062–78.
